Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $89
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Hold rating on Biomarin Pharmaceutical (BMRN) and lowers the price target from $91 to $89.
April 26, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Hold rating on Biomarin Pharmaceutical and lowers the price target from $91 to $89.
The adjustment in price target by Canaccord Genuity reflects a slight negative sentiment towards Biomarin Pharmaceutical's short-term stock price potential, but the maintenance of a Hold rating suggests a neutral outlook on the company's overall performance. The change in price target is specific and directly impacts BMRN's perceived value, but the hold rating indicates stability.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100